Background Atrial fibrillation is associated with stroke, yet approximately 50% of patients are
not treated with guideline-directed oral anticoagulants (OACs). Aims Given that the etiology …

Objective Oral anticoagulant (OAC) prescription for stroke prevention in atrial fibrillation (AF)
patients frequently does not follow current guidelines, with underuse in patients at high risk …

Background We explored patterns of and factors associated with the use of oral
anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF) in …

Background: Oral anticoagulant therapy (OAC) to prevent atrial fibrillation (AF)–related
strokes remains poorly used. Alternate strategies, such as community pharmacist …

Background Globally, over 33 million people have atrial fibrillation (AF). In eligible patients,
oral anticoagulation (OAC) is recommended for stroke risk reduction. Despite recent …

Background Real-world data on patients' and physicians' values related to the use of oral
anticoagulant (OAC) therapy for stroke prevention in patients with nonvalvular atrial …

Objective To assess the perception of the risk of stroke and the risks and benefits of oral
anticoagulation (OAC) in patients with atrial fibrillation (AF). Patients and Methods …

Background: The use of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and
low stroke risk might cause more harm than benefit. Little attention has been given to …

Objective: Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke in
patients with atrial fibrillation (AF). The study characterized the prescribing of OACs in …

Background Updated evidence-based guidelines for the management of atrial fibrillation
(AF) necessitate patient review, particularly with respect to oral anticoagulants, to ensure …